Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neovascular Age-Related Macular Degeneration (nAMD) Clear all
Not yet recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
Drug
Lead sponsor
Rophibio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI (axitinib implant), Aflibercept
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced May 22, 2026, 5:52 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Interventions
SKG0106
Genetic
Lead sponsor
Skyline Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced May 22, 2026, 5:52 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
79
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 22, 2026, 5:52 AM EDT
Enrolling by invitation Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
KHK4951, Aflibercept Injection
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced May 22, 2026, 5:52 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AKST4290, Placebo, Aflibercept
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced May 22, 2026, 5:52 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
50 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced May 22, 2026, 5:52 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced May 22, 2026, 5:52 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
95
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced May 22, 2026, 5:52 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
50
States / cities
Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 5:52 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
Interventions
GEM103, Aflibercept, Sham
Biological · Drug
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Campbell, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced May 22, 2026, 5:52 AM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Gene Therapy, AMD, Wet AMD, wAMD, nAMD
Interventions
No intervention.
Other
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced May 22, 2026, 5:52 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Interventions
EXG102-031
Biological
Lead sponsor
Exegenesis Bio
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Reno, Nevada • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 5:52 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
OCU-10-C-110 for Injection
Drug
Lead sponsor
Ocugenix Corporation
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Carmel, Indiana • Abilene, Texas • Willow Park, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 5:52 AM EDT